In the rapidly evolving landscape of human genetics, the bottleneck is no longer our ability to sequence the human genome, but our capacity to understand what those sequences actually mean. As whole-genome sequencing becomes a standard diagnostic tool, clinicians are increasingly confronted with "variants of uncertain significance" (VUS)—genetic alterations whose impact on human health remains unknown. A recent study published in Human Genetics and Genomics Advances (HGGA) by Dr. Hyung-lok Chung and his colleagues offers a blueprint for overcoming this hurdle, utilizing the humble fruit fly (Drosophila) to provide definitive functional insights into MARK2-associated neurodevelopmental disorders.
The Core Discovery: Defining the Role of MARK2
The research, titled "Loss-of-Function Variants in MARK2 Cause Neurodevelopmental Disorder," represents a significant step forward in clinical genetics. MARK2 (Microtubule Affinity Regulating Kinase 2) is a gene critical to cellular architecture and signaling. By leveraging Drosophila as a "humanized" model system, Dr. Chung’s team was able to move beyond mere association and toward a nuanced biological classification of patient-derived variants.
The study systematically analyzed eight different MARK2 variants identified in patients. By observing these variants in vivo, the researchers successfully categorized them into distinct functional tiers:
- Loss-of-function: Primarily associated with truncating variants that effectively disable the protein.
- Hypomorphic: A classification for most missense variants, where the protein retains partial function but is insufficient for normal development.
- Benign/Non-pathogenic: A surprising finding where one variant behaved identically to the wild-type, suggesting it was not the cause of the patient’s clinical presentation.
This level of resolution is a game-changer for clinicians, who often struggle to interpret the impact of a rare variant in a child presenting with developmental delays.
A Chronology of Scientific Persistence
The journey to this publication was not without its obstacles. The project originated as part of a long-standing collaboration between Dr. Chung and Dr. Wendy K. Chung, a prominent researcher in neurodevelopmental disease. While Dr. Wendy Chung’s team focused on the intensive process of patient ascertainment and genomic sequencing, Hyung-lok Chung’s laboratory provided the essential functional validation through Drosophila models.
However, science is rarely a linear path. "While we were in the middle of the project and generating good data, a separate group published a case series of MARK2-associated neurodevelopmental disorder in AJHG," Dr. Chung recalled. "That was a frustrating moment."
In the high-stakes environment of academic publishing, a competing study can often render one’s work redundant. Yet, rather than abandoning the project, the team pivoted. They recognized that the clinical report published by the other group lacked the systematic, in-vivo functional classification that their own research provided. By focusing on the biological "why" behind the clinical observations, they ensured their study offered unique, additive value to the scientific community. The project was brought to completion through the dedicated work of Dr. Yunseon Yang and Yoon-Kyung Shim, whose efforts in the fly facility were pivotal to the paper’s success.
Supporting Data: Why Drosophila?
The study serves as a robust defense of model organism-based functional genomics. Critics of Drosophila research often point to the evolutionary distance between flies and humans, but Dr. Chung argues that the fruit fly is a powerful, scalable platform for high-throughput variant analysis.
In this project, each of the eight variants was put through a gauntlet of tissue-specific assays:
- Viability: Measuring whether the presence of the variant hindered the organism’s survival.
- Lifespan: Evaluating the long-term impact on the organism’s health.
- Protein Expression: Determining if the genetic variant led to the production of stable or unstable proteins.
- Wing Patterning: A highly sensitive developmental marker used to gauge signaling pathways.
By gathering this comprehensive, multi-dimensional dataset, the team demonstrated that functional genomics is not just a secondary check, but a primary tool for interpreting the "backlog" of variants of uncertain significance. This approach provides a repeatable template that other laboratories can use to validate genes linked to other rare diseases.
The Human Impact: Implications for Families
For families dealing with a child’s neurodevelopmental disorder, a genetic diagnosis is often only the beginning. The "diagnostic odyssey"—the years-long search for answers—can leave families in a state of limbo.
"Practically, I hope this provides some clarity for families with MARK2 variants," says Dr. Chung. "A genetic diagnosis is the first step, but understanding what a variant actually does to protein function and brain development is what helps clinicians counsel families and think about next steps."
Beyond individual patient care, the study seeks to refine the criteria used by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP). By establishing MARK2 as a well-characterized NDD-associated gene, the study enables more confident clinical interpretations for future patients.
To further this goal, Dr. Chung has launched the Houston Methodist Drosophila Functional Genomics Core. This facility is specifically designed to bridge the gap between human geneticists and model organism researchers. It offers services to clinicians who have identified variants but lack the laboratory infrastructure to perform functional validation. "If you have variants of uncertain significance and are unsure how to begin functional studies, feel free to reach out," he notes.
Perspectives on the Life of a New Investigator
The publication of this study also highlights the complex realities facing the next generation of academic scientists. For Dr. Chung, the transition from postdoctoral researcher to independent investigator at the Houston Methodist Research Institute and Weill Cornell Medical College has been a steep learning curve.
"Securing grant funding as a new PI takes a lot of effort—writing proposals, going through study sections, dealing with rejections, all while trying to build a lab at the same time," he explains. He notes that the "administrative burden"—budgets, compliance, and mentoring—often threatens to stifle the creative spark required for high-level scientific inquiry.
Furthermore, the "paradox of choice" is a constant struggle. His lab possesses the capacity to investigate diverse fields—from sphingolipid metabolism to Epstein-Barr virus—and the discipline required to prioritize one path over another is perhaps the most difficult skill for a new lab head to master. "Saying ‘not yet’ to a good idea is sometimes just as important as saying ‘yes’ to the right one," he admits.
Despite these challenges, he credits the institutional environment at Houston Methodist for his ability to produce meaningful research. The support of the Department of Neurology and the robust research infrastructure provided by the Institute have allowed him to maintain his focus on the science rather than the logistics of lab management.
Future Horizons: Connecting the Rare and the Common
Looking toward the future, Dr. Chung is optimistic about the trajectory of the field. He points to recent large-scale whole-genome sequencing efforts that are identifying risk genes for common, complex neurodegenerative diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis.
Historically, these conditions have been studied primarily through genome-wide association studies (GWAS), which identify regions of the genome associated with disease risk. However, these hits often fall in non-coding regions, making it notoriously difficult to identify the specific genes involved.
"Now, with population-scale whole-genome sequencing, researchers are finding rare coding variants that carry real risk for these common diseases," Dr. Chung observes. "This starts to connect the rare and common disease worlds that have mostly been separate."
By applying the same functional genomics approach used for rare Mendelian disorders to these common conditions, the field is poised to uncover the mechanisms of disease that have remained hidden for decades. For Dr. Chung, it is a thrilling time to be a geneticist. The tools—high-speed sequencing, CRISPR, and model organism assays—are finally catching up to the ambitious questions that scientists have been asking for generations.
As his work with MARK2 demonstrates, the future of medicine lies not just in reading the code, but in understanding the functional consequences of every letter in the human genome. Through persistence, collaboration, and a commitment to rigorous functional analysis, Dr. Chung and his peers are turning the tide on diagnostic uncertainty, bringing us closer to a future where every variant has a story, and every story has a potential path toward treatment.
About the Author
